Treatments For Prostate Cancer

Posts Tagged ‘Prostate’

Product Description
Over the last several decades epidemiological, human migratory studies, pre-clinical and even early phase clinical trials have suggested that dietary constituents may offer a protective effect in reducing the incidence of multiple cancers, including cancer of the prostate. Given the potential that some of these compounds have shown in pre-clinical and even some clinical investigations, it is essential to further identify and develop promising new agents in the hope of creating a broad spectrum of cancer chemopreventive agents. In our studies, we characterized two agents for prostate cancer chemoprevention: carnosol and alpha-mangostin. Carnosol, a dietary diterpene, found in Mediterranean herbs including basil, oregano, sage, and thyme has been shown to decrease prostate cancer cell viability. In our analysis we found carnosol to function as a dual disruptor of the androgen and estrogen receptor-alpha using in vitro and in vivo models. Further study found these traits to be unique when compared to FDA approved anti-androgens and anti-estrogens. alpha-Mangostin, a dietary xanthone, isolated from the mangosteen fruit, was also observed to decrease prostate cancer cell viability. We evaluated alpha-mangostin for kinase inhibition against 50 different kinases. Of those, alpha-mangostin was found to be most effective against CDK4. Our analysis describes the in vitro and in vivo inhibition of prostate cancer using alpha-mangostin. We are proposing that alpha-mangostin and carnosol have unique mechanisms of action and may be further developed as cancer chemopreventive agents.

Selected plant constituents for the prevention and treatment of prostate cancer.

newprostatecancertreatmentsandnews.blogspot.com www.facebook.com prostatecancertreatmentcures.blogspot.com All the new and latest best treatments for prostate cancer are detailed here

Product Description
This digital document is an article from Ebony, published by Thomson Gale on September 1, 2007. The length of the article is 746 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: ‘It’s not always prostate cancer.’.(HOUSE CALL)(Disease/Disorder overview)
Author: Brian A. Stone
Publication: Ebony (Magazine/Journal)
Date: September 1, 2007
Publisher: Thomson Gale
Volume: 62 Issue: 11 Page: 46(1)

Article Type: Disease/Disorder overview

Distributed by Thomson Gale

‘It’s not always prostate cancer.’.: An article from: Ebony

Product Description
This digital document is an article from Reproductive Health Matters, published by Reproductive Health Matters on November 1, 2008. The length of the article is 4275 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: “Losing my chestnut”: one gay man’s wrangle with prostate cancer.(Essay)
Author: Gary W. Dowsett
Publication: Reproductive Health Matters (Magazine/Journal)
Date: November 1, 2008
Publisher: Reproductive Health Matters
Volume: 16 Issue: 32 Page: 145(6)

Article Type: Essay

Distributed by Gale, a part of Cengage Learning

“Losing my chestnut”: one gay man’s wrangle with prostate cancer.: An article from: Reproductive Health Matters

Product Description
This digital document is an article from Men’s Health Advisor, published by Belvoir Media Group, LLC on July 1, 2010. The length of the article is 1169 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Your doctor influences your prostate treatment choice: seek multiple opinions and weigh all of your options before deciding on a therapy for prostate cancer.(UROLOGY)
Author: Unavailable
Publication: Men’s Health Advisor (Magazine/Journal)
Date: July 1, 2010
Publisher: Belvoir Media Group, LLC
Volume: 12 Issue: 7 Page: 4(2)

Distributed by Gale, a part of Cengage Learning

Your doctor influences your prostate treatment choice: seek multiple opinions and weigh all of your options before deciding on a therapy for prostate cancer.: … An article from: Men’s Health Advisor

Product Description
This digital document is an article from Men’s Health Advisor, published by Belvoir Media Group, LLC on April 1, 2008. The length of the article is 1355 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: New approaches target only the tumors in prostate cancer: focal therapy offers the promise of selective treatment with fewer side effects but more research and better detection capabilities are necessary.(Urology)(Clinical report)
Author: Unavailable
Publication: Men’s Health Advisor (Magazine/Journal)
Date: April 1, 2008
Publisher: Belvoir Media Group, LLC
Volume: 10 Issue: 4 Page: 1(2)

Article Type: Clinical report

Distributed by Gale, a part of Cengage Learning

New approaches target only the tumors in prostate cancer: focal therapy offers the promise of selective treatment with fewer side effects but more research … An article from: Men’s Health Advisor

Product Description
The genetic and biochemical diversity of marine microorganisms makes them a promising source of useful pharmaceutical agents. The marine cyanobacterium Lyngbya majuscula produces a large number of lipopeptides that are ligands for the voltage-gated sodium channel (VGSC). Compounds that block sodium channel current are known to be effective as anticonvulsants, anesthetics, and anti-arrthymic drugs. In addition, the expression of VGSC’s was found to correlate with the metastatic potential of prostate cancer cells, indicating that sodium channel blockers could have therapeutic use as prostate cancer drugs. The jamaicamides are lipopeptides isolated from L. majuscula that exhibit sodium channel blocking activity at 5 muM. They share a common pharmacophore with the hermitamides, another class of lipopeptides isolated from the same cyanobacterium. The hermitamides are structurally less complex than the jamaicamides but have not been tested for sodium channel activity. Herein, we report the enantioselective synthesis of the hermitamides, their sodium channel activity, and effects on prostate cancer cell proliferation. We also report the enantioselective synthesis of jamaicamide C carboxylic acid. Additional work is reported targeting the dimerization interface of core binding factor (CBF), a protein implicated in the development of acute myelogenous leukemia (AML). A lead compound was designed using computational screening, NMR spectroscopy and x-ray crystallography. A large series of analogues was synthesized and tested for their ability to inhibit dimerization. We have identified several analogues that potently bind to CBF, inhibit dimerization and block proliferation of AML leukemia cell lines.

Synthesis and discovery of lipopeptides from marine sources as sodium channel blockers for the treatment of prostate cancer.

This is the CBS Cares Holiday PSA urging women to schedule a prostate exam as a gift to the man in their lives.

TheHenry Ford Vattikuti Urology Institute is a worldwide leader in the diagnosis and treatment of numerous urological conditions. Through clinical excellence, NIH-funded research investigations and protocols as well as a critical role in the teaching of the clinicians of the future, this center is consistently ranked among the best in the nation. In fact, Henry Ford Hospital was recently named a “Best Hospital” for Urology by US News and World Report for 2009. About the da Vinci Robotic Procedures The Vattikuti Urology Institute has performed more than 5000 robotic procedures. We have more experience performing robotic prostatectomy than any other surgical team in the world. Today, we are the only institution routinely offering a catheter-free approach to robotic prostatectomy. For more on Robotic Surgery, visit www.henryford.com About the Vattikuti Urology Institute Dr. Mani Menon and his surgical team offer unequaled quality and results. The Henry Ford Vattikuti Urology Institute, led by Mani Menon, MD, offers the most advanced treatments for prostate cancer, kidney disease, bladder cancer, and other urologic disease. Dr. Menon is known worldwide for developing robotic surgery for prostate cancer treatment. His robotic surgery innovations have made robotic prostatectomy the surgical standard of care for prostate cancer. Since performing the first robotic prostatectomy at Henry Ford Hospital in 2001, Dr. Menon and the Vattikuti Urology Institute team continue to have the …

Description